2026-06-14T03:38:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/113572024-09-27T23:56:36Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Letrado, Patricia author Corsini, Bruno author Díez-Martínez, Roberto author Bustamante, Noemí author Yuste, Jose Enrique author García, Pedro author 2018 To test the synergistic effect of Cpl-711 endolysin and antibiotics for antipneumococcal activity. A combination of Cpl-711 and different antibiotics (amoxicillin, cefotaxime, levofloxacin and vancomycin) was tested in a checkerboard assay against several multidrug-resistant Streptococcus pneumoniae strains. Mouse and zebrafish models of pneumococcal sepsis were used to confirm the in vitro data. The activity of Cpl-711 combined with amoxicillin or cefotaxime was synergistic in the bactericidal effect against a serotype 23F multiresistant clinical isolate of S. pneumoniae. Synergy between Cpl-711 and cefotaxime was validated using both mouse and zebrafish models. Combination of Cpl-711 and cefotaxime may help in the treatment of diseases caused by multiresistant pneumococcal strains. Future Microbiol . 2018 Sep;13(11):1215-1223. 10.2217/fmb-2018-0077 1746-0921 Future microbiology 30238774 http://hdl.handle.net/20.500.12105/11357 Streptococcus pneumoniae antibiotic multidrug-resistant endolysin mouse model synergy zebrafish model Bactericidal synergism between antibiotics and phage endolysin Cpl-711 to kill multidrug-resistant pneumococcus.